• NCI’s Report to the Nation: Cancer Rates Continue to Decline, Liver Cancer the Exception
  • A New Gene Variant May Explain Cancer-Related Outcomes in African-Americans
  • ASH's 5 New Choosing Wisely Recommendations for Hematologists
  • Advances in Multiple Myeloma Generate Excitement at ASH 2015
  • First Precision Medicine Trial in Cancer Prevention Identifies Patients for Chemoprevention
  • Medicare Will Now Reimburse Physicians for End-of-Life Discussions with Patients
  • New Scoring System Can Improve Lung Cancer Diagnosis
  • First Consensus Statement on High-Quality Palliative Care Issued by ASCO/AAHPM
  • Medicare to Cover More of the Cost of Blincyto, Citing Substantial Benefits
  • FDA Grants Priority Review for 2 Investigational Cancer Drugs
  • Current System Favors Development of Drugs for Late-Stage Cancer
  • Top US Oncologists Issue a Call to Lower Costs of Cancer Drugs, Assess Value
  • Inovio Launches Immunotherapy Trial in Prostate Cancer
  • European Regulatory Agency Grants Accelerated Review for 2 Multiple Myeloma Drugs
  • Partnership between Genomics and Big Data Companies Promotes Next-Generation Sequencing Innovation
  • Eli Lilly and Immunocore Launch New Collaboration to Develop Next-Generation Immuno-oncology Therapies
  • Biosimilars Focus on Oncology, Could Reach $55 Billion by 2020
  • ImmunoCellular Therapeutics and Novella Clinical to Collaborate on a Phase 3 Trial in Glioblastoma
  • House Passes New Medicare Bill That Includes a Value-Based Insurance Design Pilot Project

Results 1 - 6 of 6
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology